🇺🇸 FDA
Patent

US 7235534

Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )

granted A61KA61K38/00A61K39/00

Quick answer

US patent 7235534 (Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )) held by INSTITUT DE CARDIOLOGIE DE MONTREAL expires Mon Jun 21 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INSTITUT DE CARDIOLOGIE DE MONTREAL
Grant date
Tue Jun 26 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 21 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00, A61K39/00, A61P, A61P9/00